
Amid growing concern over access to Covid-19 medical products, Moderna (MRNA) has decided not to enforce its patent rights related to its experimental vaccine and will also license its intellectual property to any Covid-19 vaccines to others after the pandemic has ended.
The decision means other companies or governments should not have concerns that the biotech would seek to prevent other Covid-19 vaccines from being developed based on its technology. “We feel a special obligation under the current circumstances to use our resources to bring this pandemic to an end as quickly as possible,” the company said in a brief statement (here are the patents).
What is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
May one observe we should hope that – ““Every manufacturer of a vaccine, drug or diagnostic should follow suit … “
KEI has more commentary the Moderna statement here: https://www.keionline.org/34112